Revolu-zoldonrasib vs placebo for KRAS G12D pancreatic cancer (RMC-9805-305)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[RMC-9805-305] A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
Principal Investigator
Headshot of Niharika Bansal Mettu
Associate Professor of Medicine
Protocol Number
IRB: PRO00120109
NCT: NCT07621718
Phase
Phase III
ClinicalTrials.gov
Status
OPEN TO ACCRUAL
Participate